To assess how the Medical Staff of UNC view interventions to prevent COVID acquisition

To assess three different metrics of healthcare access as surrogate measures of immunization coverage.

This is a research study and your participation in this study is voluntary. The purpose of this study is to test if injectable, long-acting anti-HIV drugs that are given every month can be used safely and effectively in individuals who are infected with HIV and who have had problems taking daily medications in the past. The study will also look at how well these medications are tolerated.

This study is partnering with communities to identify the best ways to provide COVID-19 testing and vaccines to people who have been disproportionately affected by COVID-19. This includes communities of color, essential workers, immigrants and migrants, people in rural areas, and people with chronic diseases like diabetes and high blood pressure. We want to train community outreach workers and peer recruiters from community and faith-based organizations to help reach these underserved populations with COVID-19 testing and COVID-19 vaccines - a strategy known as "community-based task shifting." Thus, we will be conducting focus groups and theater testing sessions and questionnaires with patients who have received COVID-19 health services and focus groups and interviews with key stakeholders and theater testing sessions and questionnaires with individuals who work in community outreach or peer health education organizations for COVID-19 health services.

The purpose of this study is to see whether people living with HIV who gained a significant amount of weight after starting an antiretroviral therapy (ART) regimen that included an integrase strand transfer inhibitor (INSTI) in combination with tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir alafenamide/lamivudine (TAF/3TC) could gain less weight, or might lose weight, after an ART regimen switch. The study will also assess if a switch in ART leads to differences in metabolic conditions (how the body stores and uses energy), cardiovascular health (the heart and blood vessels), and bone health.

This is a Phase 2, randomized, open-label, active-controlled, multicenter study to evaluate the safety, efficacy, and PK (Pharmacokinetics) of ISL (Islatravir) +LEN (Lenacapavir). Virologically suppressed PWH (People living With HIV) who meet all eligibility criteria will be randomized in a 2:1 ratio to 1 of the following 2 groups: Treatment Group 1 (n = 50) Oral weekly ISL administered with LEN (ISL+LEN) Treatment Group 2 (n = 25) Oral daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)

This implementation science study will use mixed methods and an interrupted time series design to evaluate an implementation strategy intended to expand the reach and effectiveness of COVID-19 testing and vaccination services in underserved populations in the Piedmont region of NC. The primary service outcomes (i.e., reach and effectiveness) will be evaluated using review of existing routinely collected data. The primary implementation outcomes will be assessed through mixed methods research with patients who received, and providers who delivered, COVID-19 testing or prevention services, such as vaccination, at a Consortium-supported site such as a Federally Qualified Health Center administered by Piedmont Health. A standardized script will be used to inform potential participants about the study, their research options, and to screen to see if they are preliminarily eligible to take part in the study.

The purpose of this research study is to learn more about patient preferences for care when undergoing treatment for drug use-associated endocarditis (DUA-IE), specifically treatment for addiction and antibiotic treatment.

To learn more about tick-borne diseases in North Carolina, specifically how many people are infected and what symptoms they experience.

The purpose of this study is to investigate if N-803, a new experimental drug that stimulates the immune system, is safe and tolerable when given alone and in combination with two new experimental drugs that are antibodies (natural proteins that the body makes in response to an infection) to HIV (the virus that causes AIDS), VRC07-523LS and 10-1074. This study will also look at how well HIV is controlled after stopping anti-HIV medications (also known as "ART") in persons who received N-803 alone or N-803 with VRC07-523LS and 10-1074.